A Phase 1 interventional study of HM12460A in Healthy Volunteers, sponsored by Hanmi Pharmaceutical Company Limited. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-08-12.
Sponsored by Hanmi Pharmaceutical Company Limited · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a phase 1 study to assess and compare molar potency of HM12460A and glargine in healthy subjects.
Hanmi Pharmaceutical Company Limited is the lead sponsor of 191 studies on the registry; 12 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 6 (55%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intravenous (IV) infusion
Biological: HM12460A
Intravenous (IV) infusion (Dose A)
Biological: HM12460A
Intravenous (IV) infusion (Dose B)
Biological: HM12460A
Intravenous (IV) infusion (Dose C)
Biological: HM12460A
HM12460A is a long-acting insulin
Blood glucose assessment of HM12460A and insulin glargine over the entire dosing period
- Comparison of HM12460A to insulin glargine based on blood glucose profile generated by intravenous infusion
Time frame: 1 month
Cmax of HM12460A
- Maximum concentration of HM12460A over the entire dosing period
Time frame: 1 month
AUC of HM12460A
- Area Under the Curve of HM12460A over the entire dosing period
Time frame: 1 month
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Oct 2017 to primary completion in Feb 2018, 3 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: HM12460A
Hanmi Pharmaceutical Company Limited →